Latest Blogs

Sep 13, 2022
There has never been a more pertinent moment for all of us to consider how we can engage with colleagues in other countries to solve the problems of cancer. 
Aug 11, 2022
Dr. Tara Rajendran celebrates the legacy and mentorship of Dr. Karen Jean Marcus upon her retirement after 33-year career at the Dana-Farber Cancer Institute.
Jul 27, 2022
Dr. Anna M Laucis discusses the landscape and future opportunities for narrative medicine, along with her own explorations in original artwork and poetry.
Jul 21, 2022
It feels great to celebrate 17 consecutive years of organizing the Best of ASCO Lebanon meeting, including a well-received event featuring expert faculty in 2022.
Subscribe to this column

ASCO Commentary

ASCO Commentary provides an interactive platform for ASCO’s organizational leadership and senior staff to connect directly to ASCO’s membership and the wider oncology community.

Nov 03, 2021
ASCO president Dr. Everett E. Vokes and Nominating Committee chair Dr. Sharon H. Giordano have a call to action for all voting-eligible members.
Feb 21, 2018
Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.
Oct 28, 2016
Dr. Richard L. Schilsky outlines the Society's Target Agent and Profiling Utilization Registry (TAPUR) Study and similar international protocols. A global data sharing platform could greatly accelerate our ability to learn about new uses for currently approved targeted anticancer drugs.
Nov 02, 2015
Chief Medical Officer Dr. Richard L. Schilsky answers your questions about this exciting new opportunity in health care policy and advocacy.
Oct 26, 2015
Personalized cancer care is not a new concept, but its application has been enabled and enhanced by a far greater understanding of the biological underpinnings of cancer than ever existed before.
Nov 12, 2014
By Richard L. Schilsky, MD, FASCO, Chief Medical Officer of ASCO. During the past six weeks I’ve had the opportunity to attend cancer meetings in four countries on three continents. In September, I represented ASCO at the annual meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen,...

Pages